Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Everyday Seasonal Positions That Compensate Fairly in the US - 2Posts falsely claim Netanyahu video fabricated to cover up his death
- 3Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- 4Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- 5'Weezer: The Gathering' 2026 tour: How to get tickets, prices, dates and more
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- Home Plan Tips for Seniors
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Pick the Ideal Family Feline Variety for Your Home
- Catholic influencer shares death of 5-year-old son from 'severe' flu
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Truly amazing Palaces: Which Is Your Number one?
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
